Evident acquires CrestOptics to expand life science imaging

Evident has completed the acquisition of CrestOptics S.p.A., a Rome-based developer and manufacturer of advanced optical imaging systems. The deal marks the third exit this year for Primo Capital, which has supported the Italian company since its early development stages.

CrestOptics specializes in high-speed, high-content 3D imaging for the life sciences, pharmaceutical, and biotech sectors. Its product portfolio includes the X-Light family of spinning disk confocal systems, the CICERO widefield and spinning disk solution, and the DeepSIM super-resolution platform. These technologies allow researchers to observe biological samples at resolutions exceeding conventional optical microscopy.

Through this acquisition, Evident aims to broaden its life science imaging portfolio and accelerate its innovation roadmap by integrating CrestOptics’ engineering capabilities and specialized optical modules into its global production and distribution network.